Arch Biopartners Inc.
TSX VENTURE : ACH
OTCBB : FOIFF

Arch Biopartners Inc.

August 04, 2015 10:41 ET

Arch Biopartners Announces Issuance of a Second U.S. Patent for Peptide Solid Surface Interface

TORONTO, ONTARIO--(Marketwired - Aug. 4, 2015) - Arch Biopartners Inc (Arch) or (the Company) (TSX VENTURE:ACH)(OTCBB:FOIFF) announced today the U.S. Patent and Trademark Office (USPTO) has issued U.S. Patent 9,096,775 titled, "Surface Coated Structures and Methods".

This patent further protects the Company's peptide-solid surface technology which has been shown to reduce biofilm formation and corrosion on various solid surfaces and improve biocompatibility of certain plastics used in medical devices.

The issuance of this patent gives Arch commercial protection for this novel technology in the most lucrative pharmaceutical and industrial market in the world. Arch management anticipates that similar patents will be issued, in due course, in various major national markets that are members of the Patent Cooperation Treaty.

The new U.S. patent issued today is the second related to Arch's peptide solid surface interface technology. On February 25, 2015, Arch announced the USPTO issued Patent 8,961,984 bearing the same name.

Arch management plans further commercial development of the technology in medical and industrial applications in the coming year.

"This patent issuance adds to the commercial prospects of the Arch portfolio. We continue to produce data showing that our unique peptides reduce corrosion of steel and inhibit biofilm formation on various steel and plastic surfaces. We have recently seen published data from our science team showing promise to improve the biocompatibility of polysulfone used in kidney dialysis. Having another patent issued by the USPTO on our technology is another important milestone toward our commercial goals," said Richard Muruve, CEO of Arch.

The patent is based on a technology invented by Dr. Randall Irvin, Dr. Elisabeth Davis and Dr. D.Y. Li at the University of Alberta and Dr. Daniel Muruve, Chief Science Officer of Arch and Professor at University of Calgary. The new patent has been assigned to Arch.

About Arch Biopartners

Arch Biopartners is a portfolio based biotechnology company established to develop new products and technology for unmet medical needs. The Company's portfolio includes MetaMx, which targets brain tumor initiating cells; ABP569, a new treatment for respiratory Pseudomonas aeruginosa infections; and, Metablok, a potential treatment for sepsis and cancer metastasis.

Arch has also been developing its peptide-solid surface interface with the objective of reducing corrosion, biofilm formation and improving biocompatibility of various metals and plastics.

For more information on the Company, please consult the other public documents filed on SEDAR at www.sedar.com.

The Company has 53,189,679 common shares outstanding.

Forward-Looking Statements

All statements, other than statements of historical fact, in this news release are forward looking statements that involve various risks and uncertainties, including, without limitation, statements regarding the future plans and objectives of the Company. There can be no assurance that such statements will prove to be accurate. Actual results and future events could differ materially from those anticipated in such statements. These and all subsequent written and oral forward-looking statements are based on the estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. The Company assumes no obligation to update forward-looking statements should circumstances or management's estimates or opinions change.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact Information